After our first 20 issues and more than 100 AI × biology stories, a pattern is starting to emerge that no single paper, funding round, product launch, or benchmark can show on its own.
Yes, BAIO has covered a lot of news. But the point is that the news is beginning to add up. We’re starting to see a shape.
AI × biology is moving from models to systems. The bottlenecks are moving downstream. Virtual biology is climbing from proteins toward cells, patients, and physiology. Big AI companies are treating biology as a platform category.
And AI can produce impressive biological outputs. More important, though, is who validates it, who explains it, who has the right data, and who turns it into something scientists, clinicians, or companies can actually use.
So for this special report, I went back through BAIO’s first 20 issues and distilled eight signals that say where AI × biology stands in the first half of 2026.
Let’s dive in.